Verrica Pharmaceuticals (NASDAQ:VRCA) CEO Buys $399,878.64 in Stock

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) CEO Jayson Rieger bought 94,311 shares of Verrica Pharmaceuticals stock in a transaction that occurred on Tuesday, November 25th. The shares were acquired at an average price of $4.24 per share, with a total value of $399,878.64. Following the acquisition, the chief executive officer directly owned 182,593 shares of the company’s stock, valued at $774,194.32. The trade was a 106.83% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Verrica Pharmaceuticals Price Performance

VRCA stock traded up $0.40 during midday trading on Tuesday, hitting $5.12. The company’s stock had a trading volume of 262,910 shares, compared to its average volume of 116,852. Verrica Pharmaceuticals Inc. has a twelve month low of $3.28 and a twelve month high of $13.60. The company’s fifty day moving average price is $4.07 and its 200 day moving average price is $5.43. The stock has a market capitalization of $48.59 million, a P/E ratio of -1.50 and a beta of 1.71.

Verrica Pharmaceuticals (NASDAQ:VRCA) last posted its quarterly earnings data on Friday, November 14th. The company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of ($1.14) by $1.27. The business had revenue of $14.34 million for the quarter, compared to analyst estimates of $8.34 million. Equities analysts expect that Verrica Pharmaceuticals Inc. will post -1.46 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Verrica Pharmaceuticals in a research report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Reduce”.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Boothbay Fund Management LLC bought a new position in shares of Verrica Pharmaceuticals during the third quarter worth approximately $1,210,000. Bridgeway Capital Management LLC acquired a new stake in Verrica Pharmaceuticals during the third quarter worth approximately $52,000. Armistice Capital LLC increased its stake in Verrica Pharmaceuticals by 3.7% during the 2nd quarter. Armistice Capital LLC now owns 8,881,344 shares of the company’s stock worth $4,708,000 after acquiring an additional 313,944 shares during the period. Qube Research & Technologies Ltd acquired a new position in Verrica Pharmaceuticals in the 2nd quarter valued at $28,000. Finally, Marshall Wace LLP bought a new stake in shares of Verrica Pharmaceuticals during the 2nd quarter valued at $66,000. Institutional investors and hedge funds own 42.45% of the company’s stock.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.